Gubra A/S
CSE:GUBRA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
114
726
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gubra A/S
Accounts Payable
Gubra A/S
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Gubra A/S
CSE:GUBRA
|
Accounts Payable
kr11.4m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Chemometec A/S
CSE:CHEMM
|
Accounts Payable
kr11.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Gubra A/S
Glance View
Gubra ApS operates as biotechnology company. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The firm's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
See Also
What is Gubra A/S's Accounts Payable?
Accounts Payable
11.4m
DKK
Based on the financial report for Dec 31, 2023, Gubra A/S's Accounts Payable amounts to 11.4m DKK.
What is Gubra A/S's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
37%
Over the last year, the Accounts Payable growth was 8%. The average annual Accounts Payable growth rates for Gubra A/S have been 37% over the past three years .
You don't have any saved screeners yet
